BridgeBio Pharma’s acoramidis demonstrated significant reductions in all-cause mortality and recurrent cardiovascular-related hospitalizations in patients with ATTR-CM, a debilitating heart condition. The positive results from the Phase 3 ATTRibute-CM study highlight the potential of acoramidis as a first-line therapy for ATTR-CM, offering hope for improved quality of life for patients.
Dr. Deepak Krishnamurthy, head of Interventional Cardiology at Bengaluru’s Kauvery Hospital, has released a series of informative videos addressing heart attack emergencies. The videos cover vital aspects like recognizing a heart attack, administering first aid, selecting a suitable hospital, understanding treatment options, and managing lifestyle after a heart attack. Dr. Krishnamurthy emphasizes the importance of prompt medical attention in saving lives and provides clear guidance on how to navigate a heart attack emergency.
The global heart failure monitoring systems market is projected to reach a valuation of US$ 14,079.6 million in 2024 and is expected to grow at a CAGR of 5.7% during the forecast period of (2024 to 2034). This growth is fueled by the rising prevalence of cardiovascular diseases and the development of innovative devices for heart and blood vessel management.
The recent deaths of actors Sidharth Shukla, Shreyas Talpade, and Vikas Sethi, all due to heart-related issues, highlight a growing concern: the increasing prevalence of cardiovascular diseases (CVDs) among younger generations. While lifestyle and stress are often cited as contributing factors, experts are now exploring a potential link between indigestion and cardiac arrests. The case of Vikas Sethi, who experienced digestive problems shortly before his passing, raises questions about whether indigestion could serve as a warning sign for heart problems. This article delves into the possible connection between indigestion and heart attacks, emphasizing the importance of recognizing and addressing chest pain, and sheds light on the alarming trend of CVDs affecting younger populations.
A new study reveals that air pollution significantly increases the risk of heart diseases and death in cancer patients, highlighting health disparities faced by this vulnerable group. The research, published in the Journal of the American College of Cardiology, analyzed the impact of fine particulate matter (PM2.5) on cardiovascular health in cancer patients, finding it weakens the body’s defenses against inflammation and detoxification, crucial factors for both cancer and heart disease. This emphasizes the need for tailored strategies to mitigate air pollution exposure and protect cancer patients from cardiovascular risks.
Everyday habits that may seem harmless can have a significant impact on the health of our hearts. From crash dieting and eliminating certain macronutrients to poor dental health and excessive caffeine consumption, these seemingly innocuous actions can contribute to heart problems over time. Recognizing and addressing these habits can help reduce our risk of cardiovascular disease and promote long-term heart health.
A recent study has shed light on the heightened health risks faced by men with diabetes compared to women. The research, conducted by The University of Sydney, Australia, revealed that diabetic men are more prone to complications such as heart disease, leg/foot issues, kidney problems, and eye disorders.
Hypertension, commonly known as high blood pressure, is a major public health concern, affecting over 1.3 billion adults globally. Despite its significant impact on health, hypertension often goes unnoticed until complications arise. This silent killer is responsible for millions of preventable deaths each year, outnumbering other leading risk factors like smoking and high blood sugar. In India, approximately 311 million people (or one in three adults) have hypertension, and the numbers are rising alarmingly.
A new study reveals that depression and cardiovascular disease (CVD) share a common gene module, indicating a potential connection at the developmental level. The discovery provides new biomarkers for both diseases and may lead to the development of dual-purpose preventative strategies.
Around 3.6 million older Americans are now eligible for Medicare coverage of Novo Nordisk’s weight-loss drug Wegovy, following FDA approval for expanded use in reducing cardiovascular risks. The new approval allows for Medicare Part D plans to cover Wegovy for individuals who are overweight or obese and have both heart disease and obesity.
